Mistake 2: Expecting immediate results Tissue repair is a biological process that takes time
Quick Answer Neither peptide is objectively "better." Available studies indicate BPC-157 is a systemic "jack-of-all-trades" healer that accelerates repair via angiogenesis (blood vessel creation) and the nitric oxide pathway, with a profound affinity for the gastrointestinal tract and tendons
This guide explains what BPC-157 is, who it may help, how it works, the benefits and the real limits of the evidence, how it is delivered, and what treatment involves
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
Table 1 Articles excluded from the analysis after reviewing the eligibility of full-text articles
Both are commonly discussed in relation to anxiety, cognition, and neuroprotection
